http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Dec 2025 01:00:24 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html <p>BioVersys AG (SIX: BVAG) announced the initiation of its Phase 3 clinical program for BV100, an antibiotic candidate targeting ventilator-associated bacterial pneumonia caused by multi-drug resistant bacteria. The Basel-based biopharmaceutical company submitted clinical trial applications to regulatory authorities in December 2025, with first patient dosing expected in the coming months.</p> <p>The global registration study will include clinical sites across the United States, Europe, Latin America, Asia and China. BioVersys expects to report topline data from the Phase 3 trial in the second half of 2027.</p> <p>The Phase 3 trial follows Phase 2 results that showed BV100 treatment resulted in a 50% relative http://www.streetinsider.com/FDA/BioVersys+initiates+Phase+3+trial+for+antibiotic+candidate+BV100/25725482.html Thu, 11 Dec 2025 01:00:24 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Press+Releases/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html <p align="justify">Ad hoc announcement pursuant to Art. 53LR</p> <p align="justify"><strong>BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- </strong></p> <ul><li style="text-align:justify;"><strong>BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027</strong></li><li style="text-align:justify;"><strong>Significant value inflection points achieved in 2025 including: Successful IPO on SIX Swiss Exchange extending cash runway to 2028, Strong BV 100 Phase 2 data generated in VABP, Global Research Collaboration with Shionogi for BV500, alpibectir progressed to Phase 2 trial in pulmonary TB, and http://www.streetinsider.com/Globe+Newswire/BioVersys+Announces+BV100+Phase+3+Initiation+and+Provides+a+Business+Update/25725470.html Thu, 11 Dec 2025 01:00:00 -0500 A.06822034 A.19982038 A.38055885 BIOV O.01691593 O.04982061 O.08138602 O.20026344 http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html <p>BioVaxys Technology Corp. (CSE: BIOV) completed a private placement financing that raised $1,922,984.92 in gross proceeds through the sale of 11,311,676 units at $0.17 per unit.</p> <p>Each unit consists of one common share and one warrant that allows the holder to purchase an additional share at $0.40 for 24 months from the issuance date. The company used the Listed Issuer Financing Exemption under Canadian securities regulations for the offering, which means the units are not subject to resale restrictions.</p> <p>The Vancouver-based biopharmaceutical company stated the proceeds will fund pipeline growth activities including pursuing licensing opportunities and research collaborations, identifying supply sources for http://www.streetinsider.com/Equity+Offerings/BioVaxys+Technology+completes+%241.9+million+private+placement+financing/25638006.html Wed, 19 Nov 2025 15:41:15 -0500 5LB BIOV O.41051729